Study Description
The purpose of this open-label, multicenter, phase IIIb, single-arm study is to characterize the efficacy and safety of the combination of ribociclib and standard adjuvant endocrine therapy (ET) on invasive breast cancer-free survival (iBCFS), in a close to clinical practice patient population with HR-positive (HR+), HER2-negative (HER2-), Anatomic Stage Group III, IIB, and a subset of Stage IIA Early Breast Cancer (EBC). The study consists of Screening, Treatment, and Follow-up periods.
* Treatment Period: all participants who complete screening will receive ribociclib 400 mg orally once daily on days 1 to 21 of a 28-day cycle, in combination with daily ET for 36 months (approximately 39 cycles) from the date of first dose. The Treatment Period starts when the patient receives their first dose of ribociclib and ends at the time of the 30-day Safety Follow-up. All treated participants should have a Safety Follow-up call conducted 30 days after the last dose of study treatment.
* Follow-up period: participants will be followed from 30 days after study treatment (i.e., ribociclib) completion/discontinuation (i.e. 30-day Safety Follow-up) until death, withdrawal of consent, lost to follow-up, or until 48 months after the last participant has received their first dose of study treatment (i.e. End of Study \[EOS\]), whichever occurs first.
Interventions
Ansastrozole
Exemestane
Goserelin
Letrozole
Leuprolide
Ribociclib
Eligibility Criteria
Key Inclusion Criteria:
* Participant has a histologically and/or cytologically confirmed diagnosis of estrogen-receptor positive and/or progesterone receptor positive breast cancer (BC).
* Participant has HER2-negative breast cancer.
* Participants may have already received any standard neoadjuvant and/or adjuvant ET, including tamoxifen or toremifene at the time of informed consent signature, but enrollment should occur within 36 months of prior ET start date and participants should have at least 3 years remaining of endocrine adjuvant therapy.
* Participant has no contraindication to receive adjuvant ET in the study.
* Participant after surgical resection where tumor was removed completely, with the final surgical specimen microscopic margins free from tumor, and belongs to one of the following categories:
* Anatomic Stage Group III, or
* Anatomic Stage Group IIB, or
* A subset of Anatomic Stage Group IIA
* Participant has an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1 or 2.
* Participant has adequate bone marrow and organ function.
* ECG values assessed by KardiaMobile-6L device, or standard 12-lead ECG per local investigator where KardiaMobile-6L cannot be used, as:
* QTcF interval at Screening \< 450 msec (QT interval using Fridericia's correction).
* Mean resting heart rate 50-99 beats per minute (determined from the ECG).
Key Exclusion Criteria:
* Participant with distant metastases of BC beyond regional lymph nodes (Stage IV according to AJCC 8th edition) and/or evidence of recurrence after curative surgery.
* Participant is concurrently using other antineoplastic therapy with the exception of adjuvant ET.
* Participant has any other concurrent severe and/or uncontrolled medical condition.
* Clinically significant, uncontrolled heart disease and/or cardiac repolarization abnormality.
* Pregnant or breast-feeding (lactating) women or women who plan to become pregnant or breast-feed during the trial.
Other inclusion/exclusion criteria may apply
Novartis Investigative Site
Recruiting
East Melbourne,Victoria,3002,Australia
Novartis Investigative Site
Recruiting
Gateshead,New South Wales,2290,Australia
Novartis Investigative Site
Recruiting
Pokfulam,999077,Hong Kong
Novartis Investigative Site
Recruiting
Tel Aviv,6423906,Israel
Novartis Investigative Site
Recruiting
Seoul,Seocho Gu,06591,Korea, Republic of
Novartis Investigative Site
Recruiting
Incheon,405 760,Korea, Republic of
Novartis Investigative Site
Recruiting
Seoul,06273,Korea, Republic of
Novartis Investigative Site
Recruiting
Seoul,06351,Korea, Republic of
Novartis Investigative Site
Recruiting
Seoul,03722,Korea, Republic of
Novartis Investigative Site
Recruiting
Seoul,05505,Korea, Republic of
Novartis Investigative Site
Recruiting
Seoul,03080,Korea, Republic of
Novartis Investigative Site
Recruiting
Taipei,10002,Taiwan
Novartis Investigative Site
Recruiting
Cankaya Ankara,06560,Turkey
Novartis Investigative Site
Recruiting
Ankara,06230,Turkey
Novartis Investigative Site
Recruiting
Ankara,06520,Turkey
Novartis Investigative Site
Recruiting
Antalya,07070,Turkey
Novartis Investigative Site
Recruiting
Istanbul,34662,Turkey
Ocala Research Institute, Inc
Recruiting
Ocala,Florida,34474,United States
Anju Vasudevan
Hope And Healing Care
Recruiting
Hinsdale,Illinois,60521,United States
Srilata Gundala
Praneetha Achanta
Washington Hospital Center
Recruiting
Washington,District of Columbia,20010,United States
Ami Chitalia
Alaska Oncology and Hematology LLC
Recruiting
Anchorage,Alaska,99508,United States
Steven Liu
Mercy Medical Center
Recruiting
Baltimore,Maryland,21202,United States
David Andrew Riseberg
Clinical Research Alliance
Recruiting
Lake Success,New York,11042,United States
James D Olimpio
Summit Cancer Care PC
Recruiting
Savannah,Georgia,31405,United States
Mark A Taylor
Samantha Jones
Cancer Center of Kansas
Recruiting
Wichita,Kansas,67214-3728,United States
Shaker R Dakhil
Jackson Oncology Associates
Recruiting
Jackson,Mississippi,39202,United States
Justin T Baker
Nebraska Cancer Specialists
Recruiting
Omaha,Nebraska,68154,United States
Margaret Barbara Block
Worldwide Contacts
If the location of your choosing does not feature any contact detail, please reach out using the information below.